Have you been diagnosed with advanced unresectable pancreatic cancer. If so, you may be able to take part in a research study looking at the safety and tolerability of olaparib in combination with durvalumab and radiation therapy in patients with pancreatic cancer.

Do you have a newly diagnosed endometrial cancer? if so, you may be eligible to participate in a research study looking at the role the uterine and gut microbiomes play in endometrial cancer development and treatment.

Have you been diagnosed with multiple myeloma that has returned and needed to be treated again? If so, you may be able to take part in a research study looking at the safety of giving a new drug called REGN5458 (Linvoseltamab) to patients with relapsed/refractory multiple myeloma.

The purpose of this study is to increase the involvement of black breast cancer patients in clinical research trials and connect these patients with resources.

We are doing a study to learn more about how people age. We want to learn more about the patterns of natural aging and the link between the small changes your body makes (biomarkers) and quality of life.

The purpose of this research study is to better understand, from the perspective of Black patients, whether telemedicine visits make prostate cancer decision making easier or harder. The COVID-19 pandemic made it more difficult for patients to see their doctors, but care could continue by having appointments via a computer or phone, which many prostate cancer doctors used. Whether in person or remote, successfully choosing a treatment for prostate cancer often uses shared decision making (SDM), the process where doctors and patients work together to make decisions that match what matters to patients, but it is unknown whether virtual appointments make discussions better or worse. Other studies have shown that Black patients may be less satisfied with their treatment choices than non-Black patients. Therefore, it is important that we understand how to improve the same quality of care for Black patients.

To evaluate whether early drug treatment extends overall survival compared with delayed drug treatment with high-risk (chronic lymphocytic leukemia [CLL] newly diagnosed asymptomatic CLL/SLL patients.

Immune checkpoint inhibitors (ICIs) are a type of cancer treatment that work by over-activating the immune system to find and kill cancer cells. This type of treatment can sometimes lead to side effects that look like autoimmune diseases (diseases where the immune system attacks the body). We want to collects samples and clinical data from cancer patients taking ICI therapy to understand why some patients get side effects and others don't.

Have you been diagnosed with primary central nervous system (CNS) lymphoma? If so you may be able to take part in a research study looking at whether using the study drugs lenalidomide, and nivolumab can be safely used in addition to the standard treatment of primary CNS lymphoma, and which dose is the most adequate when they are used together.

The purpose of this study is to test whether giving the study drug acalabrutinib is safe and could help control B-cell Non-Hodgkin CNS lymphoma that have not gone away, or have come back, after the first round of treatment.